Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare diseases characterized by mineral imbalances, which lead to over calcification of soft tissues and under mineralization of bone. The company was founded in 2016 with technology licensed from Yale University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/15/17 | $49,000,000 | Series A |
Longitude Capital Novo Ventures Sanofi Ventures | undisclosed |
| 04/10/19 | $67,000,000 | Series A-2 |
Cowen Healthcare Investments Longitude Capital New Enterprise Associates Novo Holdings RA Capital Management Rock Springs Capital Sanofi Ventures Sofinnova Ventures | undisclosed |
